{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:34:06Z","timestamp":1785530046947,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"vor","delay-in-days":390,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mtna.2016.1","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T11:39:14Z","timestamp":1457437154000},"page":"e292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal Neovascularization"],"prefix":"10.1016","volume":"5","author":[{"given":"Yukako","family":"Taketani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Toyono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Kimakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mtna.2016.1_bib1","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1038\/mtna.2016.1_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization. Pathogenesis and inhibition","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"10.1038\/mtna.2016.1_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","article-title":"Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial","volume":"97","author":"Petsoglou","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1038\/mtna.2016.1_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"10.1038\/mtna.2016.1_bib5","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1167\/iovs.08-2805","article-title":"Bevacizumab application delays epithelial healing in rabbit cornea","volume":"50","author":"Kim","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mtna.2016.1_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tem.2014.03.012","article-title":"Diverse roles of ANGPTL2 in physiology and pathophysiology","volume":"25","author":"Kadomatsu","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"10.1038\/mtna.2016.1_bib7","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/erm.2014.19","article-title":"Angiopoietin-like-2: a multifaceted protein with physiological and pathophysiological properties","volume":"16","author":"Thorin-Trescases","year":"2014","journal-title":"Expert Rev Mol Med"},{"key":"10.1038\/mtna.2016.1_bib8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/labinvest.2012.111","article-title":"Angiopoietin-like protein 2 mediates endotoxin-induced acute inflammation in the eye","volume":"92","author":"Kanda","year":"2012","journal-title":"Lab Invest"},{"key":"10.1038\/mtna.2016.1_bib9","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1167\/iovs.12-11497","article-title":"Angiopoietin-like protein 2 is a potent hemangiogenic and lymphangiogenic factor in corneal inflammation","volume":"54","author":"Toyono","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mtna.2016.1_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and target-independent angiogenesis suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"key":"10.1038\/mtna.2016.1_bib11","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","article-title":"Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis","volume":"165","author":"Kim","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1038\/mtna.2016.1_bib12","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1167\/iovs.11-9139","article-title":"Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization","volume":"53","author":"Qazi","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mtna.2016.1_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/gt.2014.112","article-title":"Inhibition of choroidal fibrovascular membrane formation by new class of RNA interference therapeutic agent targeting periostin","volume":"22","author":"Nakama","year":"2015","journal-title":"Gene Ther"},{"key":"10.1038\/mtna.2016.1_bib14","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1038\/mtna.2015.34","article-title":"Novel types of small RNA exhibit sequence- and target-dependent angiogenesis suppression without activation of Toll-like receptor 3 in an age-related macular degeneration (AMD) mouse model","volume":"4","author":"Takanashi","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1038\/mtna.2016.1_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"key":"10.1038\/mtna.2016.1_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000108117","article-title":"Transport barriers in transscleral drug delivery for retinal diseases","volume":"39","author":"Kim","year":"2007","journal-title":"Ophthalmic Res"},{"key":"10.1038\/mtna.2016.1_bib17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/jps.23463","article-title":"Surface modification of liposomes using polymer-wheat germ agglutinin conjugates to improve the absorption of peptide drugs by pulmonary administration","volume":"102","author":"Murata","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1038\/mtna.2016.1_bib18","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1167\/iovs.11-7983","article-title":"Edaravone-loaded liposome eyedrops protect against light-induced retinal damage in mice","volume":"52","author":"Shimazaki","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1038\/mtna.2016.1_bib19","doi-asserted-by":"crossref","first-page":"e42655","DOI":"10.1371\/journal.pone.0042655","article-title":"Efficacy of a novel class of RNA interference therapeutic agents","volume":"7","author":"Hamasaki","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/mtna.2016.1_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1076\/ceyr.16.7.670.5057","article-title":"Cytokine expression in the alkali-burned cornea","volume":"16","author":"Sotozono","year":"1997","journal-title":"Curr Eye Res"},{"key":"10.1038\/mtna.2016.1_bib21","first-page":"1389","article-title":"Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1","volume":"16","author":"Zhou","year":"2010","journal-title":"Mol Vis"},{"key":"10.1038\/mtna.2016.1_bib22","first-page":"e51159","article-title":"An alkali-burn injury model of corneal neovascularization in the mouse","volume":"86","author":"Anderson","year":"2014","journal-title":"J Vis Exp"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117300331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117300331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:25:26Z","timestamp":1761873926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253117300331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":22,"alternative-id":["S2162253117300331"],"URL":"https:\/\/doi.org\/10.1038\/mtna.2016.1","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal Neovascularization","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mtna.2016.1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Official journal of the American Society of Gene & Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"e292"}}